- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01380145
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Pilot Study of recMAGE-A3 + AS15 ASCI as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subjects were enrolled sequentially following confirmation of eligibility criteria, including International Staging System (ISS) stage 1, 2, or 3 multiple myeloma with MAGE-A3 tumor antigen expression. Subjects received a total of 8 immunizations with 300 µg of recMAGE-A3 + AS15. The first immunization was administered approximately 6 to 15 weeks prior to auto-SCT (Day 0), with subsequent immunizations administered every 3 weeks (± 3 days) starting 10 days after auto-SCT (ie, Days 10, 31, 52, 73, and 94). Two additional immunizations were administered at 3-month intervals (± 7 days, ie, Days 180 and 270). No dose adjustments were allowed. Platelet counts must have been ≥ 50 x 10E9/L prior to immunization, with blood product transfusions permitted as necessary.
The process for auto-SCT comprised the following: (1) up to 3 steady-state leukopheresis procedures to collect and freeze a sufficient quantity of peripheral blood mononuclear cells (PBMCs), with the first leukopheresis performed 3 weeks (± 6 days) after the first immunization; (2) stem cell mobilization with cyclophosphamide, granulocyte-colony stimulating factor (G-CSF) and/or plerixafor; (3) high-dose melphalan (total dose 200 mg/m2) on Days -3 through -1; (4) auto-SCT on Day 0; and (5) re-infusion with thawed PBMCs on Day 3.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- New York University School of Medicine
-
New York, New York, United States, 10065
- Memorial Sloan-Kettering Cancer Center
-
New York, New York, United States, 10029
- Mount Sinai Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Symptomatic multiple myeloma, ISS stage 1, 2 or 3 within 12 months of starting therapy.
- Completion of induction therapy with VGPR, or better, by IMWG criteria. All induction myeloma therapy (oral or intravenous, including steroids) must have been discontinued for 3 weeks prior to the first immunization. Subjects did not need to have measurable disease at the time of the screening visit.
- Signed separate informed consent for stem cell mobilization and high-dose chemotherapy/auto-SCT, and was found to be eligible for SCT by standard institutional criteria.
- MAGE-A3 expression determined by immunohistochemistry (IHC) present in a bone marrow specimen or plasmacytoma specimen.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.
The following laboratory parameters within the ranges specified:
- Neutrophil count: ≥ 1.5 x 109/L
- Lymphocyte count: ≥ 0.5 x 109/L
- Platelet count: ≥ 50 x 109/L
- Serum creatinine: ≤ 2 mg/dL
- Serum bilirubin: < 1.5 x the upper limit of normal (ULN)
- Aspartate and alanine aminotransferase (AST and ALT): < 2 x ULN
- Hemoglobin: ≥ 8.0 g/dL
- International normalized ratio (INR): ≤ 1.5
- Partial thromboplastin time: ≤ 1.5 x ULN (unless known history of anti-phospholipid antibody or lupus anticoagulant)
- Age ≥ 18 years.
- Able and willing to give valid written informed consent.
Exclusion Criteria:
- Prior treatment with melphalan (Alkeran®), other than 1 cycle (4 days) of oral melphalan.
- Prior autologous or allogeneic SCT.
- Prior immunization against MAGE-A3 or other cancer-testis antigens.
- Concurrent malignancies, except for treated non-melanoma skin cancer and cervical carcinoma in situ.
- Known immunodeficiency, human immunodeficiency virus (HIV) positivity, or active hepatitis B or C.
- Known allergy or history of life-threatening reaction to G-CSF or GM-CSF.
- History of autoimmune disease (eg., rheumatoid arthritis, lupus), other than vitiligo, diabetes, or treated thyroiditis.
- History of severe allergic reactions to vaccines or unknown allergens.
- History of myocardial infarction, angina, congestive heart failure, ventricular tachyarrhythmia, stroke or transient ischemic attack within the previous 6 months.
- Other serious illnesses or co-morbid conditions (e.g., serious infections requiring antibiotics, bleeding disorders, other heart or lung conditions) that, in the opinion of the investigator, made the subject inappropriate for high-dose melphalan and auto-SCT.
- Pregnancy and breastfeeding.
- Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first immunization.
- Mental impairment that may have compromised the ability to give informed consent and comply with the requirements of the study.
- Lack of availability for immunological and clinical follow-up assessments.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: recMAGE-A3 Protein + AS15 Adjuvant
Subjects received a total of 8 pre- and post-auto-SCT immunizations with recMAGE-A3 + AS15.
|
recMAGE-A3 + AS15 was administered intramuscularly at a dose of 300 µg recMAGE-A3, with no dose adjustments permitted.
The first immunization was administered 6 to 15 week prior to auto-SCT, with subsequent immunizations administered on Days 10, 31, 52, 73, and 94 (± 3 days) and Days 180 and 270 (± 7 days) after auto-SCT.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of Safety of recMAGE-A3 + AS15
Time Frame: Continuously for up to 14 months
|
Analysis of treatment-emergent adverse events (TEAEs) reported from clinical laboratory tests, physical examinations, and vital signs, with severity graded according to the NCI CTCAE, Version 4.0.
|
Continuously for up to 14 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Induction or Augmentation of MAGE-A3-Specific Humoral Immunity
Time Frame: Baseline, first immunization, and first and second leukopheresis prior to auto-SCT; Days 31, 73, 194, 284, and 374 after auto-SCT
|
Humoral immunity was determined by enzyme-linked immunosorbent assay (ELISA) to measure the presence of circulating antibodies to MAGE-A3.
Titers against an antigen were considered significant if they were >100.
Induction of responses was considered significant if there was a change from undetectable (<100) to detectable (>100) or if there was an at least 4-fold increase in titers over time.
|
Baseline, first immunization, and first and second leukopheresis prior to auto-SCT; Days 31, 73, 194, 284, and 374 after auto-SCT
|
Induction or Augmentation of MAGE-A3-Specific Cellular Immunity
Time Frame: Baseline, first immunization, and first and second leukopheresis prior to auto-SCT; Days 31, 73, 194, 284, and 374 after auto-SCT
|
Cellular immunity was determined by enzyme-linked immunosorbent spot assay (ELISPOT) or intracellular flow cytometry to determine peripheral blood levels of interferon gamma-producing CD4+ and CD8+ T cells specific for MAGE-A3.
Results were considered significant if > 50 spots and > 2 times the number of spots to negative control were observed.
|
Baseline, first immunization, and first and second leukopheresis prior to auto-SCT; Days 31, 73, 194, 284, and 374 after auto-SCT
|
Assessment of Tumor Response
Time Frame: At 3 and 12 months after auto-SCT
|
Tumor responses were evaluated using appropriate imaging methods and were categorized according to the IMWG criteria, which includes the following response designations: Complete Response (CR): negative immunofixation on serum/urine, disappearance of soft tissue plasmacytomas, <5% plasma cells in bone marrow; Stringent CR (sCR): CR + normal free light chain (FLC) ratio and absence of clonal cells in bone marrow; Very Good Partial Response (VGPR): Serum/urine M-component detectable by immunofixation but not electropheresis OR ≥90% reduction in serum M-component + urine M-component <100 mg/24 hrs; Partial Response (PR): ≥50% reduction of serum M-protein and reduction in 24-hr urinary M-protein by ≥90% or to <200 mg/24 hrs Stable disease: not response or progression |
At 3 and 12 months after auto-SCT
|
Assessment of Survival and Time to Subsequent Therapy
Time Frame: Continuously on study and for up to 5 years post-study
|
Progression-free survival (PFS) was calculated as the date from first immunization to first observation of disease progression or death due to any cause, censored on the start date of subsequent therapy or at the last date of disease assessment for subjects without a PFS event.
Overall survival (OS) was calculated as the date from first immunization to death due to any cause, censored at the date of last follow-up for subjects who were alive at the time of the analysis.
Time to subsequent therapy was calculated as the date from first immunization to start of subsequent therapy for myeloma, censored at the date of death or last follow-up for subjects who did not receive subsequent therapy.
|
Continuously on study and for up to 5 years post-study
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Hearn J Cho, MD, PhD, Mount Sinai Hospital
- Principal Investigator: Michael Millenson, MD, Fox Chase Cancer Center
- Principal Investigator: Nikoletta Lendvai, MD, PhD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
- LGS 2009-005
- 10-051 (OTHER: Fox Chase Cancer Center)
- 10-216 (OTHER: Memorial Sloan-Kettering Cancer Center)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on recMAGE-A3 Protein + AS15 Adjuvant
-
Craig L Slingluff, JrGlaxoSmithKlineCompleted
-
European Association of Urology Research FoundationGlaxoSmithKlineTerminatedUrinary Bladder NeoplasmsFrance, Spain, Netherlands, Germany, Poland, Romania, Czechia, Italy, Russian Federation, Ukraine
-
M.D. Anderson Cancer CenterGlaxoSmithKlineCompleted
-
H. Lee Moffitt Cancer Center and Research InstituteGlaxoSmithKline; Oncovir, Inc.Terminated
-
GlaxoSmithKlineCompletedLung Cancer, Non-Small CellUnited States, Estonia, France, Korea, Republic of, United Kingdom, Germany, Japan, Russian Federation, Poland
-
European Organisation for Research and Treatment...UnknownMelanoma (Skin)France, Spain, Belgium, Germany, Italy, United Kingdom, Netherlands
-
Michael Morse, MDGlaxoSmithKlineCompletedMetastatic Breast CancerUnited States
-
U.S. Army Medical Research and Development CommandGlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR); The PATH Malaria...CompletedPlasmodium Falciparum MalariaUnited States
-
U.S. Army Medical Research and Development CommandGlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR); The PATH Malaria...CompletedMalaria | Plasmodium Falciparum MalariaUnited States
-
Enimmune CorporationCompleted